Back to search

Article

A retrospective study of anti-PD-1 combined with temozolomide adjuvant therapy for stage III resected acral melanoma

2025-07-23

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose</bold>This retrospective study was conducted to determine whether the combination of adjuvant anti-PD-1 therapy and temozolomide (TMZ) could improve the disease-free survival (DFS) of patients with resected stage III acral melanoma (AM).<bold>Method</bold>We retrospectively identified patients with resected stage III AM who had undergone adjuvant treatment with either anti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a35a573c-8a84-5922-b0d3-0d79081e2fc6
DOI
10.21203/rs.3.rs-7131325/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A retrospective study of anti-PD-1 combined with temozolomide adjuvant therapy for stage III resected acral melanomaDOI 10.21203/rs.3.rs-7131325/v1
Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.Semantic proximity
A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.Semantic proximity
Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.Semantic proximity
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.Semantic proximity
Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.Semantic proximity
Final analysis of a post-marketing surveillance study of dabrafenib and trametinib combination therapy in Japanese patients with unresectable malignant melanoma with BRAF V600 mutation.Semantic proximity
Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.Semantic proximity
Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.Semantic proximity
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.Semantic proximity
LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 TrialsSemantic proximity
Timing of Radiotherapy in Uveal Melanoma: A SEER-Based Comparison of Preoperative, Postoperative, and Intraoperative ApproachesSemantic proximity
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity
Select a neighboring publication to make it the new centre.